RARE Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
214.0M
+57.4%
136.0M
-34.4%
207.3M
+29.6%
159.9M
-4.2%
167.0M
Cost of Revenue
34.0M
+13.3%
30.0M
+2.2%
29.3M
+4.8%
28.0M
+21.7%
23.0M
Gross Profit
180.0M
+69.8%
106.0M
-40.4%
177.9M
+34.9%
131.9M
-8.4%
144.0M
Operating Expenses
255.0M
-7.3%
275.0M
-5.6%
291.2M
-3.8%
302.8M
+20.2%
252.0M
R&D
167.0M
-10.7%
187.0M
-8.0%
203.3M
-6.0%
216.2M
+31.0%
165.0M
SG&A
88.0M
+0.0%
88.0M
+0.1%
87.9M
+1.5%
86.6M
-0.4%
87.0M
Operating Income
-75000000
+55.6%
-169000000
-49.2%
-113283000
+33.7%
-170890000
-58.2%
-108000000
EBITDA
-67000000
+58.4%
-161000000
-54.1%
-104498000
+35.6%
-162284000
-63.9%
-99000000
Net Income
-92000000
+50.3%
-185000000
-43.9%
-128556000
+28.7%
-180413000
-56.9%
-115000000
EPS (Basic)
$-0.90
+51.1%
$-1.84
-42.6%
$-1.29
+28.7%
$-1.81
-54.7%
$-1.17
EPS (Diluted)
$-0.90
+51.1%
$-1.84
-42.6%
$-1.29
+28.7%
$-1.81
-54.7%
$-1.17
Shares (Diluted)
101.9M
+1.3%
100.6M
+0.8%
99.8M
+0.1%
99.8M
+1.3%
98.5M
Ultragenyx Pharmaceutical (RARE) โ€” Financials